| Literature DB >> 35111948 |
Zongyou Guo1, Chi-Kun Tong1, Joanna Jacków1, Yanne S Doucet1, Hasan E Abaci1, Wangyong Zeng1, Corey Hansen1, Ryota Hayashi1, Dominick DeLorenzo1, Avina Rami1, Alberto Pappalardo1, Ellen A Lumpkin1, Angela M Christiano1.
Abstract
Atopic dermatitis (AD), driven by interleukins (IL-4/IL-13), is a chronic inflammatory skin disease characterized by intensive pruritus. However, it is unclear how immune signaling and sensory response pathways cross talk with each other. We differentiated itch sensory neuron-like cells (ISNLCs) from iPSC lines. These ISNLCs displayed neural markers and action potentials and responded specifically to itch-specific stimuli. These ISNLCs expressed receptors specific for IL-4/IL-13 and were activated directly by the two cytokines. We successfully innervated these ISNLCs into full thickness human skin constructs. These innervated skin grafts can be used in clinical applications such as wound healing. Moreover, the availability of such innervated skin models will be valuable to develop drugs to treat skin diseases such as AD.Entities:
Keywords: atopic dermatitis; iPSCs; innervation; itch; sensory neurons; skin
Year: 2021 PMID: 35111948 PMCID: PMC8780951 DOI: 10.1002/btm2.10247
Source DB: PubMed Journal: Bioeng Transl Med ISSN: 2380-6761
FIGURE 1Schematic diagram of differentiation protocol. The treatment concentrations and durations are indicated except for days 8 and 9, when basal differentiation medium was used
FIGURE 2Immunological and morphological analysis of iNCs. iNCs were cultured on coverslips for Immunostaining (a and c–f) or morphological assessment (b). The antibodies used are indicated and DAPI (blue) staining is shown in figures a, e, and f. The morphological image was acquired with a differential interference contrast (DIC) microscope (b). The images were collected at a magnification of 10× (c–e), 20× (b and f), or 30× (a). Panel f is an enlargement of panel e (the white squares)
FIGURE 3Whole cell patch‐clamp recordings of iNCs. iNCs were placed on coverslips and the current changes of the cells were recorded while the voltage remained constant. The cells were allowed to mature in a previously described protocol (a), modified media (b), or keratinocyte coculture (c and d). The modified media was formulated by using BrainPhis (Stem Cell Technologies) to replace the DMEM/F12 in the published medium and keratinocyte coculture was conducted in the modified medium for at least 2 weeks
FIGURE 4iNC calcium responses to sensational reagents. iNCs were treated with 10 μM of mouse (mPAR‐2) or human (hPAR‐2) protease‐activated receptor 2 peptides: SLIGRL‐NH3 (mPAR‐2) and SLIGKV‐NH3 (hPAR‐2). Also, histamine (100 μM) and capsaicin (1 μM) were administered at different time points as indicated and calcium responses were monitored by Fura2
FIGURE 5H&E and Immunostaining of innervated 3D skin constructs. The skin constructs were sectioned and analyzed by H&E (a) or immunochemical staining (b) (with antibodies as indicated). The images were acquired at a magnification of 20× (a and b). Scale bar: 100 μm
FIGURE 6iNC expression of receptors for selected cytokines and calcium response to IL‐4/IL‐13 treatment. RNA was isolated from iNCs and subjected for RT‐PCR analysis (a) using published primer sequences (Table 2). Cells were treated with a combination of IL‐4/IL‐13 (20 μM/ml each) and imaged at different time points (as indicated) with a calcium indicator (Fura4) (b)
PCR primers for selected cytokine preceptors
| Genes | Oligo sequences |
|---|---|
|
| GACGTGGTCAGTGCGGATAA |
|
| CTGAAATCTGCCGGGTCGTT |
|
| CTTGCGGTGCTTGTTAACGG |
|
| CGAGTGAACGGGTACGTTTCT |
|
| CCTACGGAAACTCAGCCACC |
|
| CCCCACTTGCAGACAAATCC |
|
| CACAAGAAAAGCTCGCAGACA |
|
| GGTGGTTCAGTTTTCGCTATGTT |
Sensation mimics
| Reagents | Concentration (μM) | Sensation |
|---|---|---|
| Capsaicin | 1 | Pain |
| Menthol | 250 | Cold |
| Mustard oil | 250 | Heat |
| Chloroquine | 0.1 | Itch |
| BAM (8–22) | 10 | Itch/pain |
| mPAR‐2 | 10 | Itch |
| hPAR‐2 | 10 | Itch |
| Histamine | 100 | Itch |
Mouse PAR‐2 peptides (SLIGRL‐NH3).
Human PAR‐2 peptides (SLIGKV‐NH3).
List of antibodies
| Antibodies | Cat. No. | Vendor | Dilutions | Host |
|---|---|---|---|---|
| β3 tubulin | ab18207 | Abcam | 1:1000 | Rabbit |
| NF200 | ab72996 | Abcam | 1:25,000 | Chicken |
| MRGPX2 | ab188767 | Abcam | 1:250 | Rabbit |
| Peripherin | sc‐7604 | Santa Cruz Biotechnology | 1:200 | Goat |
| MAP2 | 4542S | Cell Signaling Technology | 1:50 | Rabbit |